{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=48",
    "query": {
      "condition": "Immunity Disorders",
      "page": 48
    },
    "page_size": 10
  },
  "pagination": {
    "page": 48,
    "page_size": 10,
    "total_count": 21205,
    "total_pages": 2121,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=49&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=47&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T23:23:23.129Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04524858",
      "title": "Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cryopyrin-Associated Periodic Syndrome"
      ],
      "interventions": [
        {
          "name": "ATI-450",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aclaris Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2020-10-23",
      "completion_date": "2021-02-25",
      "has_results": true,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-10-25T23:23:23.129Z",
      "location_count": 2,
      "location_summary": "San Diego, California • San Francisco, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04524858"
    },
    {
      "nct_id": "NCT00900055",
      "title": "Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Fanconi Anemia",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "microarray analysis",
          "type": "GENETIC"
        },
        {
          "name": "polyacrylamide gel electrophoresis",
          "type": "GENETIC"
        },
        {
          "name": "polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "reverse transcriptase-polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "western blotting",
          "type": "GENETIC"
        },
        {
          "name": "chromatography",
          "type": "OTHER"
        },
        {
          "name": "high performance liquid chromatography",
          "type": "OTHER"
        },
        {
          "name": "immunoenzyme technique",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "1 Year to 55 Years"
      },
      "enrollment_count": 213,
      "start_date": "1975-06",
      "completion_date": "2016-08-23",
      "has_results": false,
      "last_update_posted_date": "2022-07-05",
      "last_synced_at": "2026-10-25T23:23:23.129Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00900055"
    },
    {
      "nct_id": "NCT00000815",
      "title": "A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections",
        "Measles"
      ],
      "interventions": [
        {
          "name": "Attenuvax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-M-R-II",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "7 Months",
        "sex": "ALL",
        "summary": "6 Months to 7 Months"
      },
      "enrollment_count": 270,
      "start_date": null,
      "completion_date": "2001-08",
      "has_results": false,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-10-25T23:23:23.129Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000815"
    },
    {
      "nct_id": "NCT00526435",
      "title": "Evaluation of Walk With Ease in Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis"
      ],
      "interventions": [
        {
          "name": "Walk with Ease - Group",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Walk with Ease - Self",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 468,
      "start_date": "2007-10",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2011-03-24",
      "last_synced_at": "2026-10-25T23:23:23.129Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00526435"
    },
    {
      "nct_id": "NCT01423825",
      "title": "Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Sub C gp140 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59C.1 Adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium chloride",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 27,
      "start_date": "2011-08",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-10-25T23:23:23.129Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01423825"
    },
    {
      "nct_id": "NCT01616940",
      "title": "Minority AIDS Initiative Retention and Re-Engagement Project",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV/AIDS"
      ],
      "interventions": [
        {
          "name": "Enhanced Peer Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Boston University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 348,
      "start_date": "2011-09",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2017-03-22",
      "last_synced_at": "2026-10-25T23:23:23.129Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Boston, Massachusetts • Brooklyn, New York",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01616940"
    },
    {
      "nct_id": "NCT00091689",
      "title": "Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "852A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2004-09",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2008-10-27",
      "last_synced_at": "2026-10-25T23:23:23.129Z",
      "location_count": 2,
      "location_summary": "Lebanon, New Hampshire • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00091689"
    },
    {
      "nct_id": "NCT02408718",
      "title": "Assistive Device Training in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Assistive Device Training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Portland VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2015-07",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2016-09-21",
      "last_synced_at": "2026-10-25T23:23:23.129Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02408718"
    },
    {
      "nct_id": "NCT04377555",
      "title": "Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 179,
      "start_date": "2020-07-30",
      "completion_date": "2025-11-11",
      "has_results": false,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-10-25T23:23:23.129Z",
      "location_count": 26,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville Beach",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04377555"
    },
    {
      "nct_id": "NCT00288626",
      "title": "High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsing-Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Granulocyte-colony stimulating factor (G-CSF) and prednisone",
          "type": "DRUG"
        },
        {
          "name": "Carmustine, etoposide, cytarabine, and melphalan (BEAM)",
          "type": "DRUG"
        },
        {
          "name": "Autologous hematopoietic stem cell transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 25,
      "start_date": "2006-07",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2017-09-19",
      "last_synced_at": "2026-10-25T23:23:23.129Z",
      "location_count": 4,
      "location_summary": "Columbus, Ohio • Houston, Texas • Seattle, Washington",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00288626"
    }
  ]
}